RIP tanezumab? Eli Lilly, Pfizer spotlight alarming safety data for NGF pain drug in PhIII
Nearly a decade after the anti-NGF class of pain drugs was crushed by safety issues and then began a long, agonizingly slow return to late-stage testing, it may all be over soon. Pfizer and Eli Lilly posted a set of longterm outcomes from a Phase III study of tanezumab, and once they got a glimpse of the data analysts immediately started to pen last rites for the drug.
A rival therapy from Regeneron and Teva isn’t being given good odds of survival.
There were mixed efficacy results for the Pfizer/Lilly program, with only the high dose achieving a statistically significant improvement for pain and physical function over NSAIDS. And the pain data were alarming, reflecting earlier concerns spotlighted by researchers.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.